nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—CHRM3—ureter—cervical cancer	0.0552	0.14	CbGeAlD
Ziprasidone—H1F0—semen—cervical cancer	0.0396	0.1	CbGeAlD
Ziprasidone—Paresis—Topotecan—cervical cancer	0.0155	0.0841	CcSEcCtD
Ziprasidone—CHRM3—exocrine gland—cervical cancer	0.0109	0.0275	CbGeAlD
Ziprasidone—CHRM5—epithelium—cervical cancer	0.00846	0.0214	CbGeAlD
Ziprasidone—HTR1E—female gonad—cervical cancer	0.00834	0.0211	CbGeAlD
Ziprasidone—H1F0—uterine cervix—cervical cancer	0.00723	0.0183	CbGeAlD
Ziprasidone—ADRA1B—renal system—cervical cancer	0.00717	0.0181	CbGeAlD
Ziprasidone—DRD5—female reproductive system—cervical cancer	0.007	0.0177	CbGeAlD
Ziprasidone—H1F0—decidua—cervical cancer	0.00689	0.0174	CbGeAlD
Ziprasidone—H1F0—renal system—cervical cancer	0.00677	0.0171	CbGeAlD
Ziprasidone—H1F0—endometrium—cervical cancer	0.00654	0.0165	CbGeAlD
Ziprasidone—DRD5—female gonad—cervical cancer	0.00637	0.0161	CbGeAlD
Ziprasidone—H1F0—mammalian vulva—cervical cancer	0.00633	0.016	CbGeAlD
Ziprasidone—Dysmenorrhoea—Topotecan—cervical cancer	0.00621	0.0338	CcSEcCtD
Ziprasidone—H1F0—uterus—cervical cancer	0.00603	0.0152	CbGeAlD
Ziprasidone—Pulmonary embolism—Topotecan—cervical cancer	0.00564	0.0307	CcSEcCtD
Ziprasidone—H1F0—female reproductive system—cervical cancer	0.00542	0.0137	CbGeAlD
Ziprasidone—Neuropathy—Topotecan—cervical cancer	0.0053	0.0288	CcSEcCtD
Ziprasidone—Rash maculo-papular—Topotecan—cervical cancer	0.00513	0.0279	CcSEcCtD
Ziprasidone—Neoplasm—Topotecan—cervical cancer	0.0051	0.0278	CcSEcCtD
Ziprasidone—H1F0—female gonad—cervical cancer	0.00493	0.0125	CbGeAlD
Ziprasidone—H1F0—vagina—cervical cancer	0.0049	0.0124	CbGeAlD
Ziprasidone—Sepsis—Topotecan—cervical cancer	0.0049	0.0266	CcSEcCtD
Ziprasidone—Ear pain—Topotecan—cervical cancer	0.0048	0.0261	CcSEcCtD
Ziprasidone—HTR7—epithelium—cervical cancer	0.0045	0.0114	CbGeAlD
Ziprasidone—CHRM3—renal system—cervical cancer	0.00439	0.0111	CbGeAlD
Ziprasidone—HTR1A—renal system—cervical cancer	0.00437	0.0111	CbGeAlD
Ziprasidone—ADRA1A—epithelium—cervical cancer	0.00434	0.011	CbGeAlD
Ziprasidone—HTR1B—female reproductive system—cervical cancer	0.00434	0.011	CbGeAlD
Ziprasidone—Dermatitis bullous—Topotecan—cervical cancer	0.00429	0.0233	CcSEcCtD
Ziprasidone—HTR1D—female reproductive system—cervical cancer	0.0042	0.0106	CbGeAlD
Ziprasidone—Lethargy—Topotecan—cervical cancer	0.00418	0.0227	CcSEcCtD
Ziprasidone—HTR7—renal system—cervical cancer	0.00418	0.0106	CbGeAlD
Ziprasidone—KCNH2—uterine cervix—cervical cancer	0.00416	0.0105	CbGeAlD
Ziprasidone—HTR2C—female reproductive system—cervical cancer	0.00416	0.0105	CbGeAlD
Ziprasidone—ADRA2C—uterine cervix—cervical cancer	0.0041	0.0104	CbGeAlD
Ziprasidone—ADRA1A—renal system—cervical cancer	0.00403	0.0102	CbGeAlD
Ziprasidone—SLC6A4—female reproductive system—cervical cancer	0.00394	0.00997	CbGeAlD
Ziprasidone—CHRM1—female reproductive system—cervical cancer	0.00393	0.00993	CbGeAlD
Ziprasidone—ADRA2C—decidua—cervical cancer	0.00391	0.00989	CbGeAlD
Ziprasidone—KCNH2—renal system—cervical cancer	0.00389	0.00984	CbGeAlD
Ziprasidone—ADRA2C—renal system—cervical cancer	0.00384	0.00971	CbGeAlD
Ziprasidone—KCNH2—endometrium—cervical cancer	0.00376	0.00951	CbGeAlD
Ziprasidone—ADRA2C—endometrium—cervical cancer	0.00371	0.00938	CbGeAlD
Ziprasidone—Cramp muscle—Topotecan—cervical cancer	0.00369	0.0201	CcSEcCtD
Ziprasidone—ADRA2C—mammalian vulva—cervical cancer	0.00359	0.00908	CbGeAlD
Ziprasidone—CHRM3—female reproductive system—cervical cancer	0.00351	0.00889	CbGeAlD
Ziprasidone—KCNH2—uterus—cervical cancer	0.00346	0.00876	CbGeAlD
Ziprasidone—CYP3A5—uterine cervix—cervical cancer	0.00343	0.00868	CbGeAlD
Ziprasidone—ADRA2C—uterus—cervical cancer	0.00342	0.00865	CbGeAlD
Ziprasidone—HRH1—epithelium—cervical cancer	0.00336	0.0085	CbGeAlD
Ziprasidone—HTR7—female reproductive system—cervical cancer	0.00334	0.00846	CbGeAlD
Ziprasidone—HRH1—uterine cervix—cervical cancer	0.00333	0.00843	CbGeAlD
Ziprasidone—CYP1A2—renal system—cervical cancer	0.00333	0.00842	CbGeAlD
Ziprasidone—ADRA2A—uterine cervix—cervical cancer	0.00327	0.00828	CbGeAlD
Ziprasidone—Weight increased—Topotecan—cervical cancer	0.00322	0.0175	CcSEcCtD
Ziprasidone—CYP3A5—renal system—cervical cancer	0.00321	0.00812	CbGeAlD
Ziprasidone—CHRM3—female gonad—cervical cancer	0.0032	0.00809	CbGeAlD
Ziprasidone—Pneumonia—Topotecan—cervical cancer	0.00317	0.0173	CcSEcCtD
Ziprasidone—HRH1—decidua—cervical cancer	0.00317	0.00803	CbGeAlD
Ziprasidone—H1F0—lymph node—cervical cancer	0.00317	0.00802	CbGeAlD
Ziprasidone—Infestation—Topotecan—cervical cancer	0.00316	0.0172	CcSEcCtD
Ziprasidone—Infestation NOS—Topotecan—cervical cancer	0.00316	0.0172	CcSEcCtD
Ziprasidone—ADRA2A—decidua—cervical cancer	0.00312	0.00789	CbGeAlD
Ziprasidone—KCNH2—female reproductive system—cervical cancer	0.00311	0.00788	CbGeAlD
Ziprasidone—Neuropathy peripheral—Topotecan—cervical cancer	0.00309	0.0168	CcSEcCtD
Ziprasidone—Sweating—Topotecan—cervical cancer	0.00303	0.0165	CcSEcCtD
Ziprasidone—HRH1—endometrium—cervical cancer	0.00301	0.00762	CbGeAlD
Ziprasidone—Epistaxis—Topotecan—cervical cancer	0.00298	0.0162	CcSEcCtD
Ziprasidone—ADRA2A—endometrium—cervical cancer	0.00296	0.00749	CbGeAlD
Ziprasidone—HRH1—mammalian vulva—cervical cancer	0.00292	0.00737	CbGeAlD
Ziprasidone—ADRA2A—mammalian vulva—cervical cancer	0.00286	0.00724	CbGeAlD
Ziprasidone—Haemoglobin—Topotecan—cervical cancer	0.00285	0.0155	CcSEcCtD
Ziprasidone—Rhinitis—Topotecan—cervical cancer	0.00284	0.0155	CcSEcCtD
Ziprasidone—KCNH2—female gonad—cervical cancer	0.00283	0.00717	CbGeAlD
Ziprasidone—Haemorrhage—Topotecan—cervical cancer	0.00283	0.0154	CcSEcCtD
Ziprasidone—Hypoaesthesia—Topotecan—cervical cancer	0.00282	0.0153	CcSEcCtD
Ziprasidone—KCNH2—vagina—cervical cancer	0.00282	0.00713	CbGeAlD
Ziprasidone—Pharyngitis—Topotecan—cervical cancer	0.00281	0.0153	CcSEcCtD
Ziprasidone—HTR2A—epithelium—cervical cancer	0.00281	0.0071	CbGeAlD
Ziprasidone—ADRA2C—female gonad—cervical cancer	0.0028	0.00707	CbGeAlD
Ziprasidone—ADRA2C—vagina—cervical cancer	0.00278	0.00703	CbGeAlD
Ziprasidone—ADRA2A—uterus—cervical cancer	0.00273	0.0069	CbGeAlD
Ziprasidone—HTR2A—renal system—cervical cancer	0.0026	0.00659	CbGeAlD
Ziprasidone—Angiopathy—Topotecan—cervical cancer	0.00257	0.014	CcSEcCtD
Ziprasidone—Immune system disorder—Topotecan—cervical cancer	0.00256	0.0139	CcSEcCtD
Ziprasidone—Mediastinal disorder—Topotecan—cervical cancer	0.00255	0.0139	CcSEcCtD
Ziprasidone—Chills—Topotecan—cervical cancer	0.00254	0.0138	CcSEcCtD
Ziprasidone—Alopecia—Topotecan—cervical cancer	0.0025	0.0136	CcSEcCtD
Ziprasidone—HRH1—female reproductive system—cervical cancer	0.0025	0.00632	CbGeAlD
Ziprasidone—Malnutrition—Topotecan—cervical cancer	0.00247	0.0134	CcSEcCtD
Ziprasidone—ADRA2A—female reproductive system—cervical cancer	0.00245	0.0062	CbGeAlD
Ziprasidone—CYP3A4—renal system—cervical cancer	0.00241	0.0061	CbGeAlD
Ziprasidone—Back pain—Topotecan—cervical cancer	0.00239	0.013	CcSEcCtD
Ziprasidone—CYP2D6—renal system—cervical cancer	0.00237	0.006	CbGeAlD
Ziprasidone—Muscle spasms—Topotecan—cervical cancer	0.00237	0.0129	CcSEcCtD
Ziprasidone—CYP3A5—female gonad—cervical cancer	0.00234	0.00592	CbGeAlD
Ziprasidone—CYP3A5—vagina—cervical cancer	0.00233	0.00588	CbGeAlD
Ziprasidone—Anaemia—Topotecan—cervical cancer	0.00228	0.0124	CcSEcCtD
Ziprasidone—HRH1—female gonad—cervical cancer	0.00227	0.00575	CbGeAlD
Ziprasidone—HRH1—vagina—cervical cancer	0.00226	0.00571	CbGeAlD
Ziprasidone—Angioedema—Topotecan—cervical cancer	0.00225	0.0123	CcSEcCtD
Ziprasidone—ADRA2A—female gonad—cervical cancer	0.00223	0.00564	CbGeAlD
Ziprasidone—ADRA2A—vagina—cervical cancer	0.00222	0.00561	CbGeAlD
Ziprasidone—Leukopenia—Topotecan—cervical cancer	0.00221	0.012	CcSEcCtD
Ziprasidone—Cough—Topotecan—cervical cancer	0.00215	0.0117	CcSEcCtD
Ziprasidone—Chest pain—Topotecan—cervical cancer	0.0021	0.0114	CcSEcCtD
Ziprasidone—Arthralgia—Topotecan—cervical cancer	0.0021	0.0114	CcSEcCtD
Ziprasidone—Myalgia—Topotecan—cervical cancer	0.0021	0.0114	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.00209	0.0113	CcSEcCtD
Ziprasidone—HTR2A—female reproductive system—cervical cancer	0.00209	0.00527	CbGeAlD
Ziprasidone—Infection—Topotecan—cervical cancer	0.002	0.0109	CcSEcCtD
Ziprasidone—Nervous system disorder—Topotecan—cervical cancer	0.00197	0.0107	CcSEcCtD
Ziprasidone—Thrombocytopenia—Topotecan—cervical cancer	0.00197	0.0107	CcSEcCtD
Ziprasidone—Skin disorder—Topotecan—cervical cancer	0.00196	0.0106	CcSEcCtD
Ziprasidone—Hyperhidrosis—Topotecan—cervical cancer	0.00195	0.0106	CcSEcCtD
Ziprasidone—CYP3A4—female reproductive system—cervical cancer	0.00193	0.00488	CbGeAlD
Ziprasidone—Anorexia—Topotecan—cervical cancer	0.00192	0.0104	CcSEcCtD
Ziprasidone—CYP2D6—female reproductive system—cervical cancer	0.0019	0.0048	CbGeAlD
Ziprasidone—HTR2A—vagina—cervical cancer	0.00189	0.00477	CbGeAlD
Ziprasidone—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00183	0.00998	CcSEcCtD
Ziprasidone—KCNH2—lymph node—cervical cancer	0.00182	0.00461	CbGeAlD
Ziprasidone—Paraesthesia—Topotecan—cervical cancer	0.00181	0.00983	CcSEcCtD
Ziprasidone—ADRA2C—lymph node—cervical cancer	0.0018	0.00455	CbGeAlD
Ziprasidone—Dyspnoea—Topotecan—cervical cancer	0.00179	0.00976	CcSEcCtD
Ziprasidone—Dyspepsia—Topotecan—cervical cancer	0.00177	0.00964	CcSEcCtD
Ziprasidone—Decreased appetite—Topotecan—cervical cancer	0.00175	0.00952	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Topotecan—cervical cancer	0.00174	0.00945	CcSEcCtD
Ziprasidone—Fatigue—Topotecan—cervical cancer	0.00174	0.00944	CcSEcCtD
Ziprasidone—CYP2D6—female gonad—cervical cancer	0.00173	0.00437	CbGeAlD
Ziprasidone—Constipation—Topotecan—cervical cancer	0.00172	0.00937	CcSEcCtD
Ziprasidone—Feeling abnormal—Topotecan—cervical cancer	0.00166	0.00902	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Topotecan—cervical cancer	0.00165	0.00896	CcSEcCtD
Ziprasidone—Urticaria—Topotecan—cervical cancer	0.0016	0.0087	CcSEcCtD
Ziprasidone—Abdominal pain—Topotecan—cervical cancer	0.00159	0.00866	CcSEcCtD
Ziprasidone—Body temperature increased—Topotecan—cervical cancer	0.00159	0.00866	CcSEcCtD
Ziprasidone—Hypersensitivity—Topotecan—cervical cancer	0.00148	0.00807	CcSEcCtD
Ziprasidone—HRH1—lymph node—cervical cancer	0.00146	0.00369	CbGeAlD
Ziprasidone—Asthenia—Topotecan—cervical cancer	0.00144	0.00786	CcSEcCtD
Ziprasidone—ADRA2A—lymph node—cervical cancer	0.00143	0.00363	CbGeAlD
Ziprasidone—Diarrhoea—Topotecan—cervical cancer	0.00138	0.00749	CcSEcCtD
Ziprasidone—Dizziness—Topotecan—cervical cancer	0.00133	0.00724	CcSEcCtD
Ziprasidone—Vomiting—Topotecan—cervical cancer	0.00128	0.00696	CcSEcCtD
Ziprasidone—Rash—Topotecan—cervical cancer	0.00127	0.00691	CcSEcCtD
Ziprasidone—Dermatitis—Topotecan—cervical cancer	0.00127	0.0069	CcSEcCtD
Ziprasidone—Headache—Topotecan—cervical cancer	0.00126	0.00686	CcSEcCtD
Ziprasidone—Nausea—Topotecan—cervical cancer	0.0012	0.00651	CcSEcCtD
Ziprasidone—CHRM1—Signaling Pathways—NOTCH2—cervical cancer	8.12e-05	0.000193	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—MTHFR—cervical cancer	8.11e-05	0.000193	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—NOTCH2—cervical cancer	8.09e-05	0.000192	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—FGFR3—cervical cancer	8.05e-05	0.000191	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—HES1—cervical cancer	8.02e-05	0.000191	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—NOTCH2—cervical cancer	8.01e-05	0.00019	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—NOTCH2—cervical cancer	7.99e-05	0.00019	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—CASP3—cervical cancer	7.97e-05	0.000189	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—FGFR3—cervical cancer	7.94e-05	0.000189	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—NOTCH1—cervical cancer	7.9e-05	0.000188	CbGpPWpGaD
Ziprasidone—ADRA2B—Hemostasis—TP53—cervical cancer	7.9e-05	0.000188	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—TERT—cervical cancer	7.89e-05	0.000188	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—NOTCH1—cervical cancer	7.89e-05	0.000188	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—MTHFR—cervical cancer	7.88e-05	0.000187	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—NOTCH1—cervical cancer	7.84e-05	0.000186	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—TERT—cervical cancer	7.79e-05	0.000185	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—HES1—cervical cancer	7.75e-05	0.000184	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—HES1—cervical cancer	7.71e-05	0.000183	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—CTNNB1—cervical cancer	7.68e-05	0.000183	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—NOTCH1—cervical cancer	7.68e-05	0.000182	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—MTOR—cervical cancer	7.67e-05	0.000182	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—FGFR3—cervical cancer	7.6e-05	0.000181	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—NOTCH1—cervical cancer	7.55e-05	0.00018	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—HES1—cervical cancer	7.5e-05	0.000178	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—NOTCH1—cervical cancer	7.45e-05	0.000177	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—NOTCH2—cervical cancer	7.43e-05	0.000176	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—HES1—cervical cancer	7.38e-05	0.000175	CbGpPWpGaD
Ziprasidone—ADRA2C—Hemostasis—TP53—cervical cancer	7.38e-05	0.000175	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—FGFR3—cervical cancer	7.24e-05	0.000172	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—FGFR3—cervical cancer	7.15e-05	0.00017	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—NOTCH1—cervical cancer	7.14e-05	0.00017	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—CASP3—cervical cancer	7.05e-05	0.000168	CbGpPWpGaD
Ziprasidone—HTR6—Signaling by GPCR—EGFR—cervical cancer	7.04e-05	0.000167	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TERT—cervical cancer	7.03e-05	0.000167	CbGpPWpGaD
Ziprasidone—HTR7—Signaling by GPCR—EGFR—cervical cancer	7.03e-05	0.000167	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling by GPCR—EGFR—cervical cancer	6.98e-05	0.000166	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—MTHFR—cervical cancer	6.97e-05	0.000166	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling by GPCR—EGFR—cervical cancer	6.84e-05	0.000163	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—HES1—cervical cancer	6.8e-05	0.000162	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—NOTCH1—cervical cancer	6.8e-05	0.000162	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—CTNNB1—cervical cancer	6.8e-05	0.000162	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TERT—cervical cancer	6.79e-05	0.000161	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TERT—cervical cancer	6.75e-05	0.00016	CbGpPWpGaD
Ziprasidone—DRD4—Signaling by GPCR—EGFR—cervical cancer	6.73e-05	0.00016	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—CA9—cervical cancer	6.72e-05	0.00016	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—NOTCH1—cervical cancer	6.71e-05	0.000159	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—STAT3—cervical cancer	6.7e-05	0.000159	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—HES1—cervical cancer	6.69e-05	0.000159	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—HES1—cervical cancer	6.68e-05	0.000159	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—HES1—cervical cancer	6.66e-05	0.000158	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling by GPCR—EGFR—cervical cancer	6.64e-05	0.000158	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—HES1—cervical cancer	6.63e-05	0.000158	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—HES1—cervical cancer	6.57e-05	0.000156	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TERT—cervical cancer	6.57e-05	0.000156	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—HES1—cervical cancer	6.55e-05	0.000156	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TERT—cervical cancer	6.46e-05	0.000154	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—FGFR3—cervical cancer	6.45e-05	0.000153	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—MTHFR—cervical cancer	6.4e-05	0.000152	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling by GPCR—EGFR—cervical cancer	6.36e-05	0.000151	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—FGFR3—cervical cancer	6.23e-05	0.000148	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—FGFR3—cervical cancer	6.2e-05	0.000147	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—HES1—cervical cancer	6.09e-05	0.000145	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—EGFR—cervical cancer	6.09e-05	0.000145	CbGpPWpGaD
Ziprasidone—DRD1—Signaling by GPCR—EGFR—cervical cancer	6.06e-05	0.000144	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—NOTCH1—cervical cancer	6.06e-05	0.000144	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—FGFR3—cervical cancer	6.03e-05	0.000143	CbGpPWpGaD
Ziprasidone—ADRA2A—Hemostasis—TP53—cervical cancer	5.99e-05	0.000142	CbGpPWpGaD
Ziprasidone—DRD3—Signaling by GPCR—EGFR—cervical cancer	5.98e-05	0.000142	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TERT—cervical cancer	5.96e-05	0.000142	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—FGFR3—cervical cancer	5.93e-05	0.000141	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—STAT3—cervical cancer	5.93e-05	0.000141	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—MTOR—cervical cancer	5.92e-05	0.000141	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—MTOR—cervical cancer	5.91e-05	0.000141	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—MTOR—cervical cancer	5.87e-05	0.00014	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TERT—cervical cancer	5.86e-05	0.000139	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—MTHFR—cervical cancer	5.86e-05	0.000139	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TERT—cervical cancer	5.85e-05	0.000139	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—NOTCH1—cervical cancer	5.85e-05	0.000139	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TERT—cervical cancer	5.83e-05	0.000139	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—NOTCH1—cervical cancer	5.82e-05	0.000138	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TERT—cervical cancer	5.81e-05	0.000138	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TERT—cervical cancer	5.76e-05	0.000137	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—MTOR—cervical cancer	5.75e-05	0.000137	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TERT—cervical cancer	5.74e-05	0.000136	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—MTOR—cervical cancer	5.66e-05	0.000135	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—NOTCH1—cervical cancer	5.66e-05	0.000134	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—MTOR—cervical cancer	5.58e-05	0.000133	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—NOTCH1—cervical cancer	5.57e-05	0.000132	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—FGFR3—cervical cancer	5.47e-05	0.00013	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—CASP3—cervical cancer	5.44e-05	0.000129	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—CASP3—cervical cancer	5.44e-05	0.000129	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—CASP3—cervical cancer	5.4e-05	0.000128	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling by GPCR—EGFR—cervical cancer	5.4e-05	0.000128	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—EGFR—cervical cancer	5.39e-05	0.000128	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—FGFR3—cervical cancer	5.38e-05	0.000128	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—FGFR3—cervical cancer	5.37e-05	0.000128	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—FGFR3—cervical cancer	5.35e-05	0.000127	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—MTOR—cervical cancer	5.35e-05	0.000127	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—FGFR3—cervical cancer	5.34e-05	0.000127	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TERT—cervical cancer	5.33e-05	0.000127	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—CASP3—cervical cancer	5.29e-05	0.000126	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—FGFR3—cervical cancer	5.28e-05	0.000126	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—FGFR3—cervical cancer	5.27e-05	0.000125	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—CTNNB1—cervical cancer	5.25e-05	0.000125	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—CTNNB1—cervical cancer	5.24e-05	0.000125	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—EGFR—cervical cancer	5.21e-05	0.000124	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—CTNNB1—cervical cancer	5.21e-05	0.000124	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—CASP3—cervical cancer	5.21e-05	0.000124	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—EGFR—cervical cancer	5.18e-05	0.000123	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—CASP3—cervical cancer	5.14e-05	0.000122	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—NOTCH1—cervical cancer	5.13e-05	0.000122	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—TP53—cervical cancer	5.11e-05	0.000121	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—CTNNB1—cervical cancer	5.1e-05	0.000121	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—MTOR—cervical cancer	5.1e-05	0.000121	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—NOTCH1—cervical cancer	5.05e-05	0.00012	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—EGFR—cervical cancer	5.04e-05	0.00012	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—NOTCH1—cervical cancer	5.04e-05	0.00012	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—MTOR—cervical cancer	5.03e-05	0.000119	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—NOTCH1—cervical cancer	5.02e-05	0.000119	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—CTNNB1—cervical cancer	5.02e-05	0.000119	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—NOTCH1—cervical cancer	5.01e-05	0.000119	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—EGFR—cervical cancer	4.96e-05	0.000118	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—NOTCH1—cervical cancer	4.96e-05	0.000118	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—CTNNB1—cervical cancer	4.95e-05	0.000118	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—NOTCH1—cervical cancer	4.95e-05	0.000118	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—CASP3—cervical cancer	4.92e-05	0.000117	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—FGFR3—cervical cancer	4.9e-05	0.000116	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—CTNNB1—cervical cancer	4.74e-05	0.000113	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—CASP3—cervical cancer	4.69e-05	0.000111	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—CASP3—cervical cancer	4.62e-05	0.00011	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—NOTCH1—cervical cancer	4.6e-05	0.000109	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—STAT3—cervical cancer	4.57e-05	0.000109	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—EGFR—cervical cancer	4.57e-05	0.000109	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—STAT3—cervical cancer	4.57e-05	0.000109	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—STAT3—cervical cancer	4.54e-05	0.000108	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—MTOR—cervical cancer	4.54e-05	0.000108	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—TP53—cervical cancer	4.52e-05	0.000107	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—CTNNB1—cervical cancer	4.52e-05	0.000107	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—EGFR—cervical cancer	4.5e-05	0.000107	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—EGFR—cervical cancer	4.49e-05	0.000107	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—EGFR—cervical cancer	4.48e-05	0.000106	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—EGFR—cervical cancer	4.46e-05	0.000106	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—CTNNB1—cervical cancer	4.46e-05	0.000106	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—STAT3—cervical cancer	4.45e-05	0.000106	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—EGFR—cervical cancer	4.42e-05	0.000105	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—EGFR—cervical cancer	4.41e-05	0.000105	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MTOR—cervical cancer	4.38e-05	0.000104	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—STAT3—cervical cancer	4.37e-05	0.000104	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MTOR—cervical cancer	4.36e-05	0.000104	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—STAT3—cervical cancer	4.32e-05	0.000103	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MTOR—cervical cancer	4.24e-05	0.000101	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—CASP3—cervical cancer	4.18e-05	9.92e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MTOR—cervical cancer	4.17e-05	9.92e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—MTHFR—cervical cancer	4.17e-05	9.91e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—EGFR—cervical cancer	4.16e-05	9.88e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—EGFR—cervical cancer	4.15e-05	9.87e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—STAT3—cervical cancer	4.13e-05	9.82e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—EGFR—cervical cancer	4.13e-05	9.8e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—EGFR—cervical cancer	4.09e-05	9.73e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—EGFR—cervical cancer	4.04e-05	9.6e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—CASP3—cervical cancer	4.03e-05	9.58e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—CTNNB1—cervical cancer	4.02e-05	9.56e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—CASP3—cervical cancer	4.01e-05	9.53e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—EGFR—cervical cancer	3.98e-05	9.45e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—STAT3—cervical cancer	3.94e-05	9.36e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—EGFR—cervical cancer	3.92e-05	9.32e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—CASP3—cervical cancer	3.9e-05	9.27e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—STAT3—cervical cancer	3.89e-05	9.23e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—CTNNB1—cervical cancer	3.88e-05	9.23e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—CTNNB1—cervical cancer	3.86e-05	9.18e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MTOR—cervical cancer	3.85e-05	9.14e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—CASP3—cervical cancer	3.84e-05	9.12e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MTOR—cervical cancer	3.79e-05	9e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MTOR—cervical cancer	3.78e-05	8.98e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MTOR—cervical cancer	3.77e-05	8.95e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—CTNNB1—cervical cancer	3.76e-05	8.93e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—EGFR—cervical cancer	3.76e-05	8.93e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MTOR—cervical cancer	3.75e-05	8.92e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MTOR—cervical cancer	3.72e-05	8.83e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MTOR—cervical cancer	3.71e-05	8.81e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—CTNNB1—cervical cancer	3.7e-05	8.79e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—EGFR—cervical cancer	3.58e-05	8.5e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CASP3—cervical cancer	3.54e-05	8.41e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—MTHFR—cervical cancer	3.53e-05	8.39e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—EGFR—cervical cancer	3.53e-05	8.39e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—STAT3—cervical cancer	3.51e-05	8.34e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—TP53—cervical cancer	3.49e-05	8.3e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—TP53—cervical cancer	3.49e-05	8.29e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CASP3—cervical cancer	3.48e-05	8.27e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CASP3—cervical cancer	3.47e-05	8.26e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—TP53—cervical cancer	3.46e-05	8.23e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CASP3—cervical cancer	3.46e-05	8.23e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CASP3—cervical cancer	3.45e-05	8.2e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MTOR—cervical cancer	3.44e-05	8.18e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CASP3—cervical cancer	3.42e-05	8.12e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CTNNB1—cervical cancer	3.41e-05	8.11e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CASP3—cervical cancer	3.41e-05	8.1e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—TP53—cervical cancer	3.39e-05	8.06e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—STAT3—cervical cancer	3.39e-05	8.05e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—STAT3—cervical cancer	3.37e-05	8.01e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CTNNB1—cervical cancer	3.36e-05	7.98e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CTNNB1—cervical cancer	3.35e-05	7.96e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CTNNB1—cervical cancer	3.34e-05	7.93e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—TP53—cervical cancer	3.34e-05	7.93e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CTNNB1—cervical cancer	3.33e-05	7.91e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CTNNB1—cervical cancer	3.3e-05	7.83e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—TP53—cervical cancer	3.29e-05	7.83e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CTNNB1—cervical cancer	3.29e-05	7.81e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—STAT3—cervical cancer	3.28e-05	7.79e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—STAT3—cervical cancer	3.22e-05	7.66e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—EGFR—cervical cancer	3.19e-05	7.58e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CASP3—cervical cancer	3.17e-05	7.53e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—TP53—cervical cancer	3.15e-05	7.49e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—EGFR—cervical cancer	3.08e-05	7.31e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—EGFR—cervical cancer	3.06e-05	7.28e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CTNNB1—cervical cancer	3.05e-05	7.26e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—TP53—cervical cancer	3.01e-05	7.14e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—EGFR—cervical cancer	2.98e-05	7.08e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—STAT3—cervical cancer	2.97e-05	7.07e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—TP53—cervical cancer	2.97e-05	7.05e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—EGFR—cervical cancer	2.93e-05	6.96e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—STAT3—cervical cancer	2.93e-05	6.95e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—STAT3—cervical cancer	2.92e-05	6.94e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—STAT3—cervical cancer	2.91e-05	6.91e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—STAT3—cervical cancer	2.9e-05	6.89e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—STAT3—cervical cancer	2.87e-05	6.83e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—STAT3—cervical cancer	2.86e-05	6.81e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—MTHFR—cervical cancer	2.73e-05	6.48e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—EGFR—cervical cancer	2.7e-05	6.42e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TP53—cervical cancer	2.68e-05	6.36e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—STAT3—cervical cancer	2.66e-05	6.32e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—EGFR—cervical cancer	2.66e-05	6.32e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—EGFR—cervical cancer	2.65e-05	6.3e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—EGFR—cervical cancer	2.64e-05	6.28e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—EGFR—cervical cancer	2.64e-05	6.26e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—EGFR—cervical cancer	2.61e-05	6.2e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—EGFR—cervical cancer	2.6e-05	6.19e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TP53—cervical cancer	2.58e-05	6.14e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TP53—cervical cancer	2.57e-05	6.11e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TP53—cervical cancer	2.5e-05	5.94e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TP53—cervical cancer	2.46e-05	5.85e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—EGFR—cervical cancer	2.42e-05	5.75e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TP53—cervical cancer	2.27e-05	5.39e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TP53—cervical cancer	2.23e-05	5.3e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TP53—cervical cancer	2.23e-05	5.29e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TP53—cervical cancer	2.22e-05	5.28e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TP53—cervical cancer	2.21e-05	5.26e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TP53—cervical cancer	2.19e-05	5.21e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TP53—cervical cancer	2.19e-05	5.19e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TP53—cervical cancer	2.03e-05	4.83e-05	CbGpPWpGaD
